Literature DB >> 21042062

ACR Appropriateness Criteria® noninvasive clinical staging of bronchogenic carcinoma.

James G Ravenel1, Tan-Lucien H Mohammed, Benjamin Movsas, Mark E Ginsburg, Jacobo Kirsch, Feng-Ming Kong, J Anthony Parker, Gautham P Reddy, Kenneth E Rosenzweig, Anthony G Saleh.   

Abstract

In order to appropriately manage patients with lung cancer, it is necessary to properly stage the tumor. The ACR Appropriateness Criteria is designed to provide an overview of the value of different imaging techniques in the non-invasive staging of lung cancer and allow for the rational selection of imaging studies to arrive at the appropriate clinical stage.

Entities:  

Mesh:

Year:  2010        PMID: 21042062     DOI: 10.1097/RTI.0b013e3181f51e7f

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  4 in total

1.  Appropriateness of imaging for lung cancer staging in a national cohort.

Authors:  Leah M Backhus; Farhood Farjah; Thomas K Varghese; Aaron M Cheng; Xiao-Hua Zhou; Douglas E Wood; Larry Kessler; Steven B Zeliadt
Journal:  J Clin Oncol       Date:  2014-09-22       Impact factor: 44.544

Review 2.  Modern diagnostic and therapeutic interventional radiology in lung cancer.

Authors:  Wai-Kit Lee; Eddie W F Lau; Kwang Chin; Oliver Sedlaczek; Karin Steinke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

3.  Cerebral staging of lung cancer: is one single contrast-enhanced T1-weighted three-dimensional gradient-echo sequence sufficient?

Authors:  Mickaël Ohana; Mi-Young Jeung; Gauthier Bazille; Catherine Roy
Journal:  Neuroradiology       Date:  2014-05-15       Impact factor: 2.804

4.  Task-Based Model Observer Assessment of A Partial Model-Based Iterative Reconstruction Algorithm in Thoracic Oncologic Multidetector CT.

Authors:  David C Rotzinger; Damien Racine; Catherine Beigelman-Aubry; Khalid M Alfudhili; Nathalie Keller; Pascal Monnin; Francis R Verdun; Fabio Becce
Journal:  Sci Rep       Date:  2018-12-07       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.